{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:40:30Z","timestamp":1792100430371,"version":"4.4.0"},"reference-count":8,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T00:00:00Z","timestamp":1143676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives\u2002<\/jats:bold> Injectable poly\u2010<jats:sc>l<\/jats:sc>\u2010lactic acid (PLLA; Sculptra<jats:sup>\u00ae<\/jats:sup>) is widely used throughout Europe and the USA to restore volume in depressed areas of the face by stimulating neocollagenesis. Injectable PLLA was previously marketed as New\u2010Fill\u2122, which was often injected incorrectly and at too high a concentration, resulting in some physicians losing confidence in this product. Today, Sculptra<jats:sup>\u00ae<\/jats:sup> is still regarded with a degree of scepticism by some physicians, due to direct or indirect experience with New\u2010Fill. Sculptra<jats:sup>\u00ae<\/jats:sup>, both in formulation and use, is vastly superior to New\u2010Fill and clinical experience with this product dispels the myths associated with the earlier types of injectable PLLA.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> PLLA is a very safe, biodegradable compound that has been used in a wide range of medical devices for the last 30\u00a0years. In injectable form a good safety profile has been proven; however, when the device is overconcentrated, localized overstimulation of the fibroblasts can result in the formation of small lumps (subcutaneous papules), which are non\u2010pathological but nevertheless palpable by the patient. Physicians must also be trained in the injection of this device, as incorrect injection technique can cause device\u2010related adverse events.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> New product guidelines have ensured that problems with PLLA concentration have been countered, and tried and tested injection techniques have been shown to ameliorate device\u2010related adverse events, both of which are dispelling the myths associated with modern injectable PLLA.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01515.x","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T13:37:35Z","timestamp":1143725855000},"page":"2-6","source":"Crossref","is-referenced-by-count":31,"title":["Dispelling the myth: appropriate use of poly\u2010<scp>l<\/scp>\u2010lactic acid and clinical considerations"],"prefix":"10.1111","volume":"20","author":[{"given":"NJ","family":"Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,30]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.820270904"},{"key":"e_1_2_4_3_2","unstructured":"Sculptra product information. Dermik Laboratories a business of sanofi\u2010aventis US LLC Bridgewater NJ USA.http:\/\/www.sculptra.com"},{"key":"e_1_2_4_4_2","first-page":"58","article-title":"Le New Fill","volume":"8","author":"Laglenne S","year":"2000","journal-title":"Objectif Peau"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2005.31709"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.2310\/6350.2005.31250"},{"key":"e_1_2_4_7_2","first-page":"56","article-title":"Six simple steps to Sculptra success: expert advice for incorporating this new filler agent into your practice","volume":"13","author":"Werschler W","year":"2005","journal-title":"Skin and Aging"},{"key":"e_1_2_4_8_2","first-page":"526","article-title":"Facial enhancement and the European experience with poly\u2010l\u2010lactic acid","volume":"3","author":"Vleggaar D","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.03.001"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01515.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01515.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:10:42Z","timestamp":1695762642000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01515.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,30]]},"references-count":8,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01515.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01515.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,30]]}}}